Submit pre-approval-window promotional materials during preapproval review

AI-verifiedblockerBinding lawCheckable — presence or a literal match settles it

Rule

For a biological product under accelerated-approval consideration, if any promotional materials (including promotional labeling and advertisements) are intended for dissemination or publication within 120 days after anticipated marketing approval, the applicant must submit copies of that material to FDA during the preapproval review period, unless FDA has instructed otherwise.

Check

Confirm that any promotional piece slated for use within 120 days after approval was submitted to FDA for review during the preapproval review period (i.e., before or during the approval decision process, not only after approval). A violation is a piece intended for early post-approval use that was never submitted to FDA during that window, absent documented instruction from FDA excusing submission.

Escalate when

Escalate if it is unclear whether the material was intended for use within the first 120 days post-approval, whether it was actually submitted to FDA in that window, or whether FDA had otherwise excused submission.

Where this comes from

21 CFR 601.45. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… § 601.45 Promotional materials. For biological products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval. After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement. …

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 601.45
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: d9573263989a646e8cdea14f…

Applies when

Productbiologic

Approval pathwayaccelerated

Launch stagepre-approval

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The source text imposes a direct obligation in mandatory terms ('applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials ... intended for dissemination or publication within 120 days following marketing approval'). The rule statement restates that obligation without adding scope: same actor (applicant), same object (promotional materials including promotional labeling and advertisements), same trigger (intended use within 120 days after approval), same timing (during the preapproval review period).
- Not overstated: the rule preserves the regulation's own escape clause ('unless otherwise informed by the agency') as 'unless FDA has instructed otherwise', and does not convert a conditional duty into an unconditional one. It also does not extend the duty to materials outside the 120-day window, which the sentence does not cover.
- Atomic: a single checkable requirement — submission of in-scope material during the preapproval review period. The parenthetical listing of labeling and advertisements enumerates the covered material rather than adding a second independently checkable duty.
- Determinism 'deterministic' is correct: the violation turns on whether a submission exists and when it was made, plus whether the piece is slated for use inside a defined 120-day window. None of this depends on impression, adequacy, prominence or balance; where the underlying facts are unknown the rule routes to escalation rather than to a judgment call.
- Authority 'binding' is correct: 21 CFR 601.45 is a codified regulation, not guidance.
- applies_when is defensible. 'launch-stage: pre-approval' matches the preapproval review period; 'product-type: biologic' matches 'biological products'. The 'approval-pathway: accelerated' limit is not spelled out in the excerpt itself, but the excerpt does carry an express scope limit — 'being considered for approval under this subpart' — and the cited locator (21 CFR 601.45, subpart E) is the accelerated-approval subpart, so naming the pathway narrows rather than broadens the rule and keeps it from being applied to ordinary BLA products.
- Severity 'blocker' is defensible: disseminating a piece that was required to be, and was not, submitted to FDA is a regulatory violation, not a stylistic defect; it should stop use rather than generate a comment.
- Locator '21 CFR 601.45' matches the source citation and the quoted sentence appears verbatim in the source text.

Nearby rules

US-ADM-010